Related Experiment Video
Updated: Aug 11, 2026

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections
Published on: August 11, 2012
[Cellular immunity in patients with urogenital chlamydiosis]
Insights
Cellular immunity chain abnormalities affect over 60% of urogenital chlamydiosis patients. Comprehensive immune status assessment is crucial for effective treatment strategies.
Area of Science:
- Immunology
- Infectious Diseases
Context:
- Urogenital chlamydiosis (UGC) is a prevalent infection.
- Cellular immunity plays a critical role in managing UGC.
- Previous studies have indicated immune system dysregulation in UGC patients.
Purpose:
- To investigate cellular immunity chain (CIC) abnormalities in patients with urogenital chlamydiosis.
- To determine the necessity of a comprehensive immune status evaluation for effective UGC treatment.
Summary:
- A study involving patients with urogenital chlamydiosis revealed significant cellular immunity chain (CIC) impairments in 63.04% of cases.
- Key findings include altered T-helper (CD3+, CD4+), activated T-lymphocyte (CD3+, CD25+), cytotoxic T-lymphocyte (CD3+, CD8+), B-lymphocyte (CD3+, CD19+), and NK-cell (CD3-, CD56+) levels.
- The research highlights that evaluating lymphocyte subpopulations alone is insufficient for a complete immune system assessment.
Impact:
- Findings underscore the need for a holistic immune status assessment in UGC patients, incorporating humoral immunity, phagocyte function, non-specific resistance, and cytokine profiles.
- This comprehensive approach is essential for developing adequate and effective treatment regimens for urogenital chlamydiosis.
- Identifies specific immunological markers that may serve as targets for therapeutic interventions.
Abstract:
Abnormalities in the cellular immunity chain (CIC) were found in 63.04% of patients with urogenital chlamydiosis (UGC) within a study of cellular immunity in patients with the above pathology. According to the study results, the below listed were the main CIC impairments: a lack or reaction to the inducer of T-helpers (CD3+ and CD4+), and to activated T-lymphocytes (CD3+ and CD25+); higher counts of cytotoxic T-lymphocytes (CD3+ and CD8+), a higher content of B-lymphocytes (CD3+ and CD19+, and lower counts of NK-cells (CD3- and CD56+). However, research of the lymphocyte subpopulation alone is not enough to evaluate adequately the immune system of a patient. In order to choose an adequate scheme for the treatment of UGH patients it is necessary to undertake a study of the immune status that should comprise, apart CIC investigations, the following: humoral immunity, phagocyte function, factors of non-specific body resistance and cytokine status.
Related Concept Videos
Cell-mediated Immune Responses
Sexually Transmitted Infections
Urinary Tract Infection II: Pathophysiology
Bacterial Phylum Chlamydiae
Microbiota of the Urogenital Tract
Trichomoniasis

